Star Lake Bioscience Co (SHSE:600866) Short-Term Debt: ¥4,606 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600866 Star Lake Bioscience Co Inc SHSE:600866
71 GF Score
Price ¥4.25
GF Value ¥5.92
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Star Lake Bioscience Co Short-Term Debt?

Star Lake Bioscience Co SHSE:600866 71 Short-Term Debt is ¥4,606 Mil as of Jun. 2026. GuruFocus rates SHSE:600866 with a GF Score™ of 71/100 and a GF Value™ of ¥5.92 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Star Lake Bioscience Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥4,606 Mil.

Star Lake Bioscience Co's quarterly Short-Term Debt declined from Dec. 2025 (¥2,914 Mil) to Mar. 2026 (¥2,836 Mil) but then increased from Mar. 2026 (¥2,836 Mil) to Jun. 2026 (¥4,606 Mil).

Star Lake Bioscience Co's annual Short-Term Debt declined from Dec. 2023 (¥1,201 Mil) to Dec. 2024 (¥1,008 Mil) but then increased from Dec. 2024 (¥1,008 Mil) to Dec. 2025 (¥2,914 Mil).

Star Lake Bioscience Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Star Lake Bioscience Co Short-Term Debt Related Terms

Star Lake Bioscience Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Star Lake Bioscience Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Star Lake Bioscience Co Short-Term Debt Chart

Star Lake Bioscience Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,558.27 2,004.21 1,201.09 1,007.58 2,913.66

Star Lake Bioscience Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,697.22 4,016.07 2,913.66 2,836.21 4,606.16
SHSE:600866
71GF Score
Star Lake Bioscience Co Inc SHSE:600866
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥4,606 Mil mean?
Star Lake Bioscience Co (SHSE:600866) has a Short-Term Debt of ¥4,606 Mil as of Jun. 2026.
Is Star Lake Bioscience Co's Short-Term Debt too high?
Star Lake Bioscience Co's current Short-Term Debt is ¥4,606 Mil. Overall, Star Lake Bioscience Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's Short-Term Debt compare to VRTX and REGN?
Star Lake Bioscience Co's Short-Term Debt of ¥4,606 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Star Lake Bioscience Co's current Short-Term Debt is ¥4,606 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.92, compared to a current price of ¥4.25 — trading 28.2% below its estimated fair value. The current Short-Term Debt is ¥4,606 Mil. Star Lake Bioscience Co's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current Short-Term Debt is ¥4,606 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?

Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued. The current stock price of ¥4.25 is trading 28.2% below its estimated GF Value™ of ¥5.92. GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.

Key valuation signals for SHSE:600866:

  • Short-Term Debt: ¥4,606 Mil
  • GF Value™: ¥5.92 vs. price of ¥4.25 (28.2% below fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Star Lake Bioscience Co Business Description

Address No. 67 Gongnong North Road, Guangdong Province, Zhaoqing, CHN, 526060
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
71GF Score

Get the complete analysis for SHSE:600866

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.25
Price
¥5.92
GF Value